Bladder Cancer

CMS has issued a permanent billing and reimbursement J-code, J9183, for the gemcitabine intravesical system (Inlexzo) in NMIBC.

Historically, treating patients with urothelial carcinoma who were considered cisplatin-ineligible due to insufficient kidney function was a signifcant unmet need; however with enfortumab vedotin entering the frontline space, these patients have another option open to them.

With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses practice-changing presentations from the 2026 ASCO GU Cancers Symposium.

Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: traditional chemotherapy or biomarker-driven therapy.

The FDA approved a label change for nadofaragene firadenovec-vncg (Adstiladrin) in non–muscle-invasive bladder cancer to improve preparation time.

Nadofaragene firadenovec-vncg (Adstiladrin) received an expanded NCCN recommendation for patients with BCG-unresponsive NMIBC.

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical guidelines for bladder cancer, according to the manufacturer.

Dr. Antoni Vilaseca Cabo discusses using an intravesical drug delivery system to continuously administer the FGFR inhibitor erdafitinib directly into the bladder, marking the first mutation-directed therapy for non-muscle invasive bladder cancer that offers patients an oncologically beneficial and bladder-sparing option with minimal toxicity.

Sacituzumab govitecan plus pembrolizumab may enable bladder preservation in MIBC.

A supplemental Biologics License Application has been submitted for nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors.

Dr Ghatalia discusses RETAIN-2, highlighting ctDNA analysis drawn from RETAIN-1 and RETAIN-2.

Induction ipilimumab/nivolumab plus chemoradiotherapy consolidation was associated with bladder preservation in muscle-invasive urothelial carcinoma.

AKY-1189 gains fast track designation in urothelial cancer.

IMvigor011 shows post-cystectomy ctDNA timing and levels predict relapse, while adjuvant atezolizumab clears ctDNA and extends survival in MIBC.

The phase 3 IMvigor011 trial represents a landmark shift toward personalized, biomarker-driven adjuvant therapy in muscle-invasive bladder cancer.

Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient subgroups that suggest further evaluation in subsequent studies.

An integrated analysis of the RETAIN-1 and RETAIN-2 trials demonstrates that circulating tumor DNA is a powerful prognostic indicator for metastatic recurrence in muscle-invasive bladder cancer.

Phase 2 results showed efficacy and tolerability of disitamab vedotin in pretreated HER2+ and HER2-low urothelial cancer.

Neoadjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival and overall survival compared with gemcitabine plus cisplatin.

FDA strengthens capecitabine and 5‑FU labels: DPD deficiency can trigger fatal toxicity; consider testing, lower doses, and prompt antidote.

During his presentation at the 4th Annual Miami Cancer Institute Precision Oncology Symposium, Petros Grivas, MD, PhD, FASCO, provided a detailed roadmap for community oncologists with an emphasis on precision medicine.

Explore the vital role of community oncology in GU cancer treatment, bridging research and real-world applications for better patient care.

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent high-grade bladder cancer, emphasizing patient-centered care.

A groundbreaking bladder cancer treatment, TAR-200, offers new hope for patients failing first-line therapy, showcasing impressive response rates and ease of use.

New combination therapy shows a 96% survival rate in patients with BCG-unresponsive bladder cancer, offering a promising alternative to radical cystectomy.